ABSTRACT
With most solid tumors, the estimation of life expectancy is related to tumor stage
at diagnosis and staging is directly linked to treatment indication. By contrast,
in patients with hepatocellular carcinoma (HCC) the prediction of prognosis is more
complex. There is no worldwide consensus on the use of any HCC staging system. Classifications
that take into account only one of the relevant prognostic parameters, such as tumor,
nodes, and metastasis (TNM) or Child-Pugh staging, are useless. Several scoring systems
have been developed, but unfortunately their major capacity is to identify end-stage
patients and they do not link staging with therapy. The Barcelona Clinic Liver Cancer
(BCLC) staging system was developed according to the results of cohort studies and
randomized clinical trials. It considers tumor stage, liver functional status, physical
status, and cancer-related symptoms and, by dividing patients into early, intermediate,
advanced, and end-stage categories, provides a link to treatment indication.
KEYWORDS
Hepatocellular carcinoma - staging - prognosis - treatment
REFERENCES
- 1
Bruix J, Sherman M, Llovet J M et al..
Clinical management of hepatocellular carcinoma: conclusions of the Barcelona-2000
EASL conference.
J Hepatol.
2001;
35
421-430
- 2
Fattovich G, Stroffolini T, Zagni I, Donato F.
Hepatocellular carcinoma in cirrhosis: incidence and risk factors.
Gastroenterology.
2004;
127(5 suppl 1)
S35-S50
- 3 American Joint Committee on Cancer. AJCC Cancer Staging Handbook. New York; Springer
2002
- 4
Pugh R N, Murray-Lyon I M, Dawson J L et al..
Transection of the oesophagus for bleeding oesophageal varices.
Br J Surg.
1973;
60
646-649
- 5
Kamath P S, Wiesner R H, Malinchoc M et al..
A model to predict survival in patients with end-stage liver disease.
Hepatology.
2001;
33
464-470
- 6
Sorensen J B, Klee M, Palshof T, Hansen H H.
Performance status assessment in cancer patients. An inter-observer variability study.
Br J Cancer.
1993;
67
773-775
- 7
Schag C C, Heinrich R L, Ganz P A.
Karnofsky performance status revisited: reliability, validity, and guidelines.
J Clin Oncol.
1984;
2
187-193
- 8
Primack A, Vogel C L, Kyalwazi S K et al..
A staging system for hepatocellular carcinoma: prognostic factors in Ugandan patients.
Cancer.
1975;
35
1357-1364
- 9
Chlebowski R T, Tong M, Weissman J et al..
Hepatocellular carcinoma. Diagnostic and prognostic features in North American patients.
Cancer.
1984;
53
2701-2706
- 10
Attali P, Prod'Homme S, Pelletier G et al..
Prognostic factors in patients with hepatocellular carcinoma. Attempts for the selection
of patients with prolonged survival.
Cancer.
1987;
59
2108-2111
- 11
Falkson G, Cnaan A, Schutt A J et al..
Prognostic factors for survival in hepatocellular carcinoma.
Cancer Res.
1988;
48
7314-7318
- 12
Calvet X, Bruix J, Gines P et al..
Prognostic factors of hepatocellular carcinoma in the west: a multivariate analysis
in 206 patients.
Hepatology.
1990;
12
753-760
- 13
Stuart K E, Anand A J, Jenkins R L.
Hepatocellular carcinoma in the United States. Prognostic features, treatment outcome,
and survival.
Cancer.
1996;
77
2217-2222
- 14
A new prognostic system for hepatocellular carcinoma: a retrospective study of 435
patients. The Cancer of the Liver Italian Program (CLIP) investigators.
Hepatology.
1998;
28
751-755
- 15
Llovet J M, Bustamante J, Castells A et al..
Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the
design and evaluation of therapeutic trials.
Hepatology.
1999;
29
62-67
- 16
Villa E, Moles A, Ferretti I et al..
Natural history of inoperable hepatocellular carcinoma: estrogen receptors' status
in the tumor is the strongest prognostic factor for survival.
Hepatology.
2000;
32
233-238
- 17
Llovet J M, Bru C, Bruix J.
Prognosis of hepatocellular carcinoma: the BCLC staging classification.
Semin Liver Dis.
1999;
19
329-338
- 18
Chevret S, Trinchet J C, Mathieu D et al..
A new prognostic classification for predicting survival in patients with hepatocellular
carcinoma. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire.
J Hepatol.
1999;
31
133-141
- 19
Leung T W, Tang A M, Zee B et al..
Construction of the Chinese University Prognostic Index for hepatocellular carcinoma
and comparison with the TNM staging system, the Okuda staging system, and the Cancer
of the Liver Italian Program staging system: a study based on 926 patients.
Cancer.
2002;
94
1760-1769
- 20
Kudo M, Chung H, Osaki Y.
Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and
limitations, and a proposal for a new staging system, the Japan Integrated Staging
Score (JIS score).
J Gastroenterol.
2003;
38
207-215
- 21
Omagari K, Honda S, Kadokawa Y et al..
Preliminary analysis of a newly proposed prognostic scoring system (SLiDe score) for
hepatocellular carcinoma.
J Gastroenterol Hepatol.
2004;
19
805-811
- 22
Tateishi R, Yoshida H, Shiina S et al..
Proposal of a new prognostic model for hepatocellular carcinoma: an analysis of 403
patients.
Gut.
2005;
54
419-425
- 23
Altman D G, Royston P.
What do we mean by validating a prognostic model?.
Stat Med.
2000;
19
453-473
- 24
Okuda K, Ohtsuki T, Obata H et al..
Natural history of hepatocellular carcinoma and prognosis in relation to treatment.
Study of 850 patients.
Cancer.
1985;
56
918-928
- 25
Schoniger-Hekele M, Muller C, Kutilek M et al..
Hepatocellular carcinoma in Central Europe: prognostic features and survival.
Gut.
2001;
48
103-109
- 26
Herold C, Reck T, Fischler P et al..
Prognosis of a large cohort of patients with hepatocellular carcinoma in a single
European centre.
Liver.
2002;
22
23-28
- 27
Prospective validation of the CLIP score: a new prognostic system for patients with
cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP)
investigators.
Hepatology.
2000;
31
840-845
- 28
Farinati F, Rinaldi M, Gianni S, Naccarato R.
How should patients with hepatocellular carcinoma be staged? Validation of a new prognostic
system.
Cancer.
2000;
89
2266-2273
- 29
Ueno S, Tanabe G, Sako K et al..
Discrimination value of the new western prognostic system (CLIP score) for hepatocellular
carcinoma in 662 Japanese patients. Cancer of the Liver Italian Program.
Hepatology.
2001;
34
529-534
- 30
Levy I, Sherman M.
Staging of hepatocellular carcinoma: assessment of the CLIP, Okuda, and Child-Pugh
staging systems in a cohort of 257 patients in Toronto.
Gut.
2002;
50
881-885
- 31
Kudo M, Chung H, Haji S et al..
Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS
score compared with the CLIP score.
Hepatology.
2004;
40
1396-1405
- 32
Grieco A, Pompili M, Caminiti G et al..
Prognostic factors for survival in patients with early-intermediate hepatocellular
carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging
systems in a single Italian centre.
Gut.
2005;
54
411-418
- 33
Marrero J, Fontana R, Barrat A et al..
Prognosis of hepatocellular carcinoma: comparison of seven staging systems in an American
cohort.
Hepatology.
2005;
41
707-716
- 34
Llovet J M, Burroughs A, Bruix J.
Hepatocellular carcinoma.
Lancet.
2003;
362
1907-1917
- 35
Cillo U, Bassanello M, Vitale A et al..
The critical issue of hepatocellular carcinoma prognostic classification: which is
the best tool available?.
J Hepatol.
2004;
40
124-131
- 36
Barbara L, Benzi G, Gaiani S et al..
Natural history of small untreated hepatocellular carcinoma in cirrhosis: a multivariate
analysis of prognostic factors of tumor growth rate and patient survival.
Hepatology.
1992;
16
132-137
- 37
Livraghi T, Bolondi L, Buscarini L et al..
No treatment, resection and ethanol injection in hepatocellular carcinoma: a retrospective
analysis of survival in 391 patients with cirrhosis. Italian Cooperative HCC Study
Group.
J Hepatol.
1995;
22
522-526
- 38
Ebara M, Ohto M, Shinagawa T et al..
Natural history of minute hepatocellular carcinoma smaller than three centimeters
complicating cirrhosis. A study in 22 patients.
Gastroenterology.
1986;
90
289-298
- 39
Bruix J, Llovet J M, Castells A et al..
Transarterial embolization versus symptomatic treatment in patients with advanced
hepatocellular carcinoma: results of a randomized, controlled trial in a single institution.
Hepatology.
1998;
27
1578-1583
- 40
Castells A, Bruix J, Bru C et al..
Treatment of hepatocellular carcinoma with tamoxifen: a double-blind placebo-controlled
trial in 120 patients.
Gastroenterology.
1995;
109
917-922
- 41
Llovet J M, Fuster J, Bruix J.
Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma:
resection versus transplantation.
Hepatology.
1999;
30
1434-1440
- 42
Wayne J D, Lauwers G Y, Ikai I et al..
Preoperative predictors of survival after resection of small hepatocellular carcinomas.
Ann Surg.
2002;
235
722-730
- 43
Vauthey J N, Lauwers G Y, Esnaola N F et al..
Simplified staging for hepatocellular carcinoma.
J Clin Oncol.
2002;
20
1527-1536
- 44
Ikai I, Arii S, Kojiro M et al..
Reevaluation of prognostic factors for survival after liver resection in patients
with hepatocellular carcinoma in a Japanese nationwide survey.
Cancer.
2004;
101
796-802
- 45
Torzilli G, Makuuchi M, Inoue K et al..
No-mortality liver resection for hepatocellular carcinoma in cirrhotic and noncirrhotic
patients: is there a way? A prospective analysis of our approach.
Arch Surg.
1999;
134
984-992
- 46
Bruix J, Castells A, Bosch J et al..
Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value
of preoperative portal pressure.
Gastroenterology.
1996;
111
1018-1022
- 47
Poon R T, Fan S T, Ng I O et al..
Different risk factors and prognosis for early and late intrahepatic recurrence after
resection of hepatocellular carcinoma.
Cancer.
2000;
89
500-507
- 48
Imamura H, Matsuyama Y, Tanaka E et al..
Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular
carcinoma after hepatectomy.
J Hepatol.
2003;
38
200-207
- 49
Mazzaferro V, Regalia E, Doci R et al..
Liver transplantation for the treatment of small hepatocellular carcinomas in patients
with cirrhosis.
N Engl J Med.
1996;
334
693-699
- 50
Plessier A, Codes L, Consigny Y et al..
Underestimation of the influence of satellite nodules as a risk factor for post-transplantation
recurrence in patients with small hepatocellular carcinoma.
Liver Transpl.
2004;
10(suppl 2)
S86-S90
- 51
Sala M, Llovet J M, Vilana R et al..
Initial response to percutaneous ablation predicts survival in patients with hepatocellular
carcinoma.
Hepatology.
2004;
40
1352-1360
- 52
Llovet J M, Real M I, Montanya X et al..
Arterial embolization, chemoembolization versus symptomatic treatment in patients
with unresectable hepatocellular carcinoma: a randomized controlled trial.
Lancet.
2002;
359
1734-1739
- 53
Bruix J, Boix L, Sala M, Llovet J M.
Focus on hepatocellular carcinoma.
Cancer Cell.
2004;
5
215-219
- 54
Takayama T, Makuuchi M, Hirohashi S et al..
Early hepatocellular carcinoma as an entity with a high rate of surgical cure.
Hepatology.
1998;
28
1241-1246
Jordi BruixM.D.
BCLC Group. Liver Unit, Hospital Clínic, University of Barcelona, Institut d’Investigacions
Biomèdiques August Pi i Sunyer
Villarroel 170, 08036 Barcelona, Spain
Email: bruix@ub.edu
